Back to top

Analyst Blog

Dr. Reddy's Laboratories Ltd. (RDY - Analyst Report) recently announced that the launch of its bioequivalent generic version of Novartis AG’s (NVS - Analyst Report) Zometa (zoledronic acid 4 mg/5 mL) Injection in the US.

Zometa is indicated for the treatment for hypercalcemia of malignancy. It is also used to reduce and delay bone complications due to multiple myeloma and bone metastases from solid tumors. Zometa is used with anti-cancer medicines. Zometa sales in 2012 were $1.3 billion.

Dr. Reddy's had received tentative approval for the Abbreviated New Drug Application (ANDA) for the generic version of Zometa from the US FDA (Food and Drug Administration) in Sep 2011.

In Jan 2013, Dr. Reddy's launched its generic version of Merck & Co., Inc.’s (MRK - Analyst Report) Clarinex Reditabs (desloratadine 2.5 mg and 5 mg) in the US. Clarinex Reditabs is indicated for the treatment of seasonal allergic rhinitis, perennial allergic rhinitis and chronic idiopathic urticaria. According to IMS Health, Clarinex Reditabs generated US revenues of approximately $5.3 million for the 12 months ending Nov 2012.

Dr. Reddy’s has a robust generic product pipeline. Dr. Reddy’s has 65 ANDAs pending approval with the FDA, of which 35 are Para IV filings and 8 are first-to-file. Revenues of the Global Generics segment were up 24% year over year to $380 million in 2012. Strong sales in North America and in other market territories were primarily responsible for the growth displayed by the Global Generics division.

The stock carries a Zacks Rank #3 (Hold). Another generic player, Mylan Inc. (MYL - Analyst Report) carries a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%